National Research (NASDAQ:NRC) Releases Quarterly Earnings Results

National Research (NASDAQ:NRC) released its earnings results on Tuesday. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.46, Zacks reports. National Research had a return on equity of 122.73% and a net margin of 6.52%.The business had revenue of $35.39 million for the quarter, compared to analyst estimates of $34.90 million.

National Research Price Performance

NRC stock traded up $1.07 on Tuesday, reaching $22.34. 112,155 shares of the company’s stock were exchanged, compared to its average volume of 108,783. The stock has a fifty day moving average of $20.38 and a 200-day moving average of $18.31. National Research has a twelve month low of $11.01 and a twelve month high of $23.25. The firm has a market cap of $508.15 million, a PE ratio of 57.28 and a beta of 0.35. The company has a quick ratio of 0.52, a current ratio of 0.52 and a debt-to-equity ratio of 5.48.

Hedge Funds Weigh In On National Research

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. lifted its stake in shares of National Research by 14.9% in the fourth quarter. Invesco Ltd. now owns 21,598 shares of the company’s stock valued at $405,000 after purchasing an additional 2,799 shares during the period. Public Employees Retirement System of Ohio increased its holdings in National Research by 13.2% in the fourth quarter. Public Employees Retirement System of Ohio now owns 88,207 shares of the company’s stock valued at $1,656,000 after buying an additional 10,312 shares in the last quarter. Squarepoint Ops LLC purchased a new position in National Research in the fourth quarter valued at about $311,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of National Research during the 4th quarter valued at approximately $60,000. Finally, PCM Encore LLC acquired a new stake in shares of National Research during the 4th quarter valued at approximately $252,000. 47.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on NRC shares. Citizens Jmp began coverage on shares of National Research in a research report on Monday, June 22nd. They issued a “market outperform” rating and a $23.00 price objective on the stock. Weiss Ratings upgraded shares of National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.00.

National Research Company Profile

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.